A large number of studies have shown that the mutation rate of K-Ras gene in pancreatic cancer patients can reach more than 90%, and the product of K-Ras gene expression is K-Ras protein with GTPase activity (Jelski and Mroczko, 2019). This evidence concerns the gene KRAS and pancreatic neoplasm.